aTYR PHARMA INCATYREarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
Revenue
$190.0K
Gross Profit
N/A
Operating Profit
$-26.7M
Net Profit
$-25.7M
Gross Margin
N/A
Operating Margin
-14076.3%
Net Margin
-13549.5%
YoY Growth
N/A
EPS
$-0.26
aTYR PHARMA INC Q3 FY2025 Financial Summary
aTYR PHARMA INC reported revenue of $190.0K for Q3 FY2025, with a net profit of $-25.7M (down 49.2% YoY) (-13549.5% margin).
Key Financial Metrics
| Total Revenue | $190.0K |
|---|---|
| Net Profit | $-25.7M |
| Gross Margin | N/A |
| Operating Margin | -14076.3% |
| Report Period | Q3 FY2025 |
aTYR PHARMA INC Annual Revenue by Year
aTYR PHARMA INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $190.0K).
| Year | Annual Revenue |
|---|---|
| 2025 | $190.0K |
| 2024 | $235.0K |
aTYR PHARMA INC Quarterly Revenue & Net Profit History
aTYR PHARMA INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | N/A | N/A |
| Q3 FY2025 | $190.0K | — | $-25.7M | -13549.5% |
| Q2 FY2025 | $0 | — | $-19.5M | N/A |
| Q1 FY2025 | $0 | — | $-14.9M | N/A |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $-17.3M | N/A |
| Q2 FY2024 | $0 | — | $-16.3M | N/A |
| Q1 FY2024 | $235.0K | — | $-15.5M | -6591.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $235000 | $0 | $0 | $0 | $0 | $0 | $190000 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $113.3M | $105.9M | $91.6M | $96.8M | $97.2M | $101.5M | $106.7M | $93.0M |
| Liabilities | $28.8M | $24.3M | $26.3M | $26.8M | $22.2M | $26.7M | $26.4M | $25.5M |
| Equity | $84.5M | $81.6M | $65.3M | $70.0M | $75.0M | $74.8M | $80.2M | $67.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.4M | $-20.4M | $-13.2M | $-69.1M | $-15.4M | $-13.9M | $-20.5M | $-62.0M |